FDA Approves Intravenous Treatment for Adrenal Gland Cancer

The FDA approved Progenics’ Azedra (iobenguane I 131), an intravenous drug used to treat rare tumors of the adrenal gland in patients aged 12 and older who cannot have them surgically removed.

The radiation therapy, which received FDA’s fast track, breakthrough therapy and priority review designations, can help reduce tumor size in patients and has been shown to lessen their need for blood pressure medication.

Azedra is approved for patients in whom the adrenal gland tumors have spread beyond the original site and require systemic anticancer therapy.